<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846739</url>
  </required_header>
  <id_info>
    <org_study_id>PROXY2</org_study_id>
    <nct_id>NCT03846739</nct_id>
  </id_info>
  <brief_title>Dose-dependent Effects of Oxytocin on the Amygdala and Reward System</brief_title>
  <official_title>Dose-dependent Effects of Oxytocin on the Amygdala and Reward System Vary Between Women and Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether effects of intranasal oxytocin on amygdala
      and reward system responses vary as a function of treatment dose in women in comparison to
      men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the present study is to determine whether intranasal oxytocin (IN-OXT)
      effects on blood oxygenation level-dependent functional magnetic resonance imaging (BOLD
      fMRI) in the amygdala and striatal regions (putamen, nucleus accumbens, caudate, pallidum)
      vary as a function of dose. In particular, the investigators plan to compare effects of three
      different IN-OXT doses (6, 12, and 24 international units, IU) on established neural and
      behavioural correlates of emotion processing in women. Results will be discussed in
      comparison to a previous study of OXT kinetics in men.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neural substrates of emotion processing, measured via blood-oxygen-level dependent signal in the amygdala</measure>
    <time_frame>45 min after nasal spray administration</time_frame>
    <description>Functional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate amygdala responses to emotional faces, because previous studies found sex-specific effects of oxytocin on amygdala activation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neural substrates of emotion processing, measured via blood-oxygen-level dependent signal in striatal regions (putamen, nucleus accumbens, caudate, pallidum)</measure>
    <time_frame>45 min after nasal spray administration</time_frame>
    <description>Functional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli. The investigators specifically plan to investigate striatal responses to emotional faces to explore sex-specific effects of OXT on reward-related brain activation.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oxytocin &amp; Placebo, 6 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal administration, 6 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin &amp; Placebo, 12 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal administration,12 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin &amp; Placebo, 24 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal administration, 24 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.</description>
    <arm_group_label>Oxytocin &amp; Placebo, 12 IU</arm_group_label>
    <arm_group_label>Oxytocin &amp; Placebo, 24 IU</arm_group_label>
    <arm_group_label>Oxytocin &amp; Placebo, 6 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo nasal sprays contain identical ingredients except for the peptide itself.</description>
    <arm_group_label>Oxytocin &amp; Placebo, 12 IU</arm_group_label>
    <arm_group_label>Oxytocin &amp; Placebo, 24 IU</arm_group_label>
    <arm_group_label>Oxytocin &amp; Placebo, 6 IU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female volunteers

          -  Right-handed

          -  Non-smoker

        Exclusion Criteria:

          -  Current psychiatric or physical illness

          -  Hormonal contraception

          -  Psychoactive medication

          -  MRI contraindication (e.g. metal in body, claustrophobia)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rene Hurlemann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://renehurlemann.squarespace.com/welcome/</url>
    <description>Neuromodulation of Emotion (NEMO) research group</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>February 27, 2019</last_update_submitted>
  <last_update_submitted_qc>February 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Rene Hurlemann</investigator_full_name>
    <investigator_title>Chair of the Medical Psychology Division and Deputy Chair of the Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>amygdala</keyword>
  <keyword>reward</keyword>
  <keyword>oxytocin</keyword>
  <keyword>dose</keyword>
  <keyword>emotion processing</keyword>
  <keyword>sex differences</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

